Long-Term Response to Pembrolizumab in Metastatic Metaplastic Breast Carcinoma: A Case Report - PubMed

2 days ago

Metaplastic breast carcinoma (MpBC) is a rare triple-negative subtype with poor response to conventional chemotherapy.
A 52-year-old patient with metastatic MpBC showed marked shrinkage of tumors after switching to pembrolizumab-based chemoimmunotherapy, despite initial tumor growth.
Treatment caused Grade 2 adverse events including adrenal insufficiency, but pembrolizumab was continued, leading to long-term disease control for over 30 months.
The case suggests pembrolizumab combination therapy may be effective for metastatic MpBC, especially in PD-L1-positive cases.

Hasty Briefsbeta